Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01665599 · ClinicalTrials.gov registry record · Phase 3

A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel

A Phase 3 study of Adult Male Hypogonadism, sponsored by Ferring Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
180
Enrollment target
19
Study locations

NCT01665599 is a Phase 3 study of Adult Male Hypogonadism that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 180 participants. The trial reports 19 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01665599, a Phase 3 study of Adult Male Hypogonadism, has completed, sponsored by Ferring Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
180 participants
Enrollment target
19
Study locations

Study Summary

This is a Phase 3 clinical trial in adult hypogonadal males with baseline serum testosterone concentrations \<300 ng/dL. The purpose of this study is to evaluate the safety and efficacy of testosterone gel (2%) delivered using an applicator.

Conditions Studied

Interventions

  • DRUG Testosterone gel (FE 999303)

Study Locations (19)

California

  • California Professional Research - Newport Beach
  • San Diego Sexual Medicine - San Diego

New York

  • University Urology - New York
  • Premier Medical Group of the Hudson Valley - Poughkeepsie

South Carolina

  • Coastal Carolina Research Center - Mt. Pleasant
  • Carolina Urologic Research Center - Myrtle Beach

Ontario

  • St. Joseph's Healthcare - London
  • Private Practice and Clinical Research - North Bay

Alabama

  • Medical Affiliated Research Cente - Huntsville

Connecticut

  • Connecticut Clinical Research - Middlebury

Florida

  • South Florida Medical Research - Aventura

Michigan

  • Michigan Institute of Urology - Saint Clair Shores

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2012-07
Est. Completion 2013-05
Phase Phase 3

Sponsor

Ferring Pharmaceuticals

83 total trials

What the Registry Record Tells You About NCT01665599

The ClinicalTrials.gov registry entry for NCT01665599 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Adult Male Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which Testosterone gel (FE 999303) is the first listed.

NCT01665599 reports 19 study locations spanning 15 distinct geographic areas - top geographies include California, New York, South Carolina.

Frequently Asked Questions

What is clinical trial NCT01665599 about?

NCT01665599 is a clinical study titled "A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel". This is a Phase 3 clinical trial in adult hypogonadal males with baseline serum testosterone concentrations \<300 ng/dL. The purpose of this study is to evaluate the safety and efficacy of testosterone gel (2%) delivered using an applicator.

What is the current status of trial NCT01665599?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2012-07. Estimated completion is 2013-05.

What conditions does trial NCT01665599 study?

This clinical trial studies the following conditions: Adult Male Hypogonadism.

What interventions are being tested in trial NCT01665599?

The interventions under investigation include: Testosterone gel (FE 999303) (DRUG).

Who is sponsoring clinical trial NCT01665599?

This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01665599 being conducted?

This trial has 19 study locations across Alabama, California, Connecticut, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.